Oncology
3 drugs are in development for Metastatic Castration-resistant Prostate Cancer.
- Companies
- 3
- Clinical trials
- 47
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Metastatic Castration-resistant Prostate Cancer pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Phase 2(2)
| Drug | Company |
|---|---|
| FG-3246 | KYNTRA BIO INC. (KYNB) |
| ngm120 | NGM BIOPHARMACEUTICALS INC (NGM) |
Phase 1(1)
| Drug | Company |
|---|---|
| JANX007 | Janux Therapeutics, Inc. (JANX) |
About this indication
Metastatic Castration-resistant Prostate Cancer context
Oncology·MeSH: Prostatic Neoplasms (D011471)
Narrower concept of MeSH descriptor Prostatic Neoplasms
Prevalence
256.0 / 100K
Incidence
111.0 / 100K/yr
Frequently asked questions
How many drugs are in development for Metastatic Castration-resistant Prostate Cancer?
BioSniper tracks 3 drugs in development for Metastatic Castration-resistant Prostate Cancer across 3 companies.
How many clinical trials target Metastatic Castration-resistant Prostate Cancer?
There are 47 clinical trials targeting Metastatic Castration-resistant Prostate Cancer tracked by BioSniper.
What is the prevalence of Metastatic Castration-resistant Prostate Cancer?
The estimated prevalence of Metastatic Castration-resistant Prostate Cancer is approximately 256.0 per 100,000 population.